Hosted on MSN
Wedbush downgrades Replimune Group (REPL)
Fintel reports that on April 13, 2026, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 641.98% Upside As of April 9, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Replimune Group, Inc. is among the best biotech stocks to invest in. TheFly reported on April 13 that Jefferies cut its ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Stock futures cautious on Monday as investors reacted to a breakdown in peace talks between the U.S. and Iran over the weekend. Tensions spiked after President Donald Trump threatened a military ...
Macworld explains how Apple uses “binned” chips—processors with disabled cores due to manufacturing defects—to create more affordable products like the iPhone 17e and entry-level MacBook Air. This ...
Nestlé has rolled out a new set of items to jump in on that World Cup hype, as they have released the new Toll House Soccer Ball-Shaped Morsels. You have two options ...
Forbes contributors publish independent expert analyses and insights. Heather Wishart-Smith is a board director who covers innovation. Flag of USA on a processor, CPU Central processing Unit or GPU ...
April 10 (Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Replimune's (REPL.O), opens new tab drug for advanced skin cancer, citing insufficient data from studies, ...
Hosted on MSN
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays
・Analysts estimate about 116% upside for REPL, compared to a 124% upside for IOVA from current levels. ・Amtagvi, already approved for melanoma, helped Iovance generate about $264 million in product ...
It was August 21, 2021. The world was still recovering from the Covid pandemic and restaurants had barely started doing regular business. So, you can imagine how surprised the staff of Asha's, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results